Analyst Price Targets — LFMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 5:48 pm | Scott Schoenhaus | KeyBanc | $5.00 | $3.45 | TheFly | LifeMD price target lowered to $5 from $8 at KeyBanc |
| August 6, 2026 1:13 pm | — | Lake Street | $5.00 | $3.41 | TheFly | LifeMD price target lowered to $5 from $8 at Lake Street |
| August 6, 2026 11:16 am | — | Mizuho Securities | $7.00 | $3.68 | TheFly | LifeMD price target lowered to $7 from $8 at Mizuho |
| August 6, 2026 9:57 am | — | BTIG | $9.00 | $3.68 | TheFly | LifeMD price target lowered to $9 from $10 at BTIG |
| May 27, 2026 10:49 am | Yi Chen | H.C. Wainwright | $10.00 | $4.24 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on LifeMD Inc (LFMD) |
| March 12, 2026 2:07 pm | Ilya Zubkov | Loop Capital Markets | $10.00 | $3.88 | StreetInsider | LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets |
| November 24, 2025 7:41 pm | Ilya Zubkov | Loop Capital Markets | $8.00 | $3.97 | StreetInsider | LifeMD Inc (LFMD) PT Lowered to $8 at Freedom Capital Markets |
| November 19, 2025 1:33 pm | Steven Valiquette | Mizuho Securities | $6.00 | $3.99 | TheFly | LifeMD price target lowered to $6 from $8 at Mizuho |
| November 19, 2025 11:31 am | Scott Schoenhaus | KeyBanc | $8.00 | $3.99 | TheFly | LifeMD price target lowered to $8 from $12 at KeyBanc |
| November 18, 2025 11:49 am | — | BTIG | $10.00 | $4.09 | TheFly | LifeMD price target lowered to $10 from $18 at BTIG |
Latest News for LFMD
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47. 3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3. 5 million, improving approximately 21% sequentially. Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided…
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LFMD.
U.S. House Trading
No House trades found for LFMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.